search
Back to results

Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19 (ONSCOVID19)

Primary Purpose

COVID-19

Status
Unknown status
Phase
Phase 2
Locations
Saudi Arabia
Study Type
Interventional
Intervention
Oral supplement enriched in antioxidants
cellulose-containing placebo capsules
Sponsored by
King Saud University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for COVID-19 focused on measuring COVID-19, Antioxidant ONS, Cytokine storm

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Confirmed SARS-CoV-2 infection
  • COVID-19 patient in stable condition (i.e., not requiring ICU admission).

Exclusion Criteria:

  • Tube feeding or parenteral nutrition.
  • Pregnant or lactating women
  • Admission to ICU > 24 hours
  • participation in another study including any forms of supplementation or disease specific ONS.

Sites / Locations

  • Prince Mohamed BinAbdulaziz HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Intervention

Placebo

Arm Description

the intervention groups will receive daily oral antioxidant supplement enriched in vitamin A, C, E, Selenium and Zinc. The composition of one capsule of the intervention-supplement includes: 1500 mcg vitamin A (as β-carotene), 250 mg Vitamin C, 90 mg vitamin E, 15 ug Selenium, and 7.5 mg Zinc.

Placebo group will receive daily intervention in form of cellulose-containing gelatin capsules with the same color and shape.

Outcomes

Primary Outcome Measures

Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial
Changes in scores of the NRS-2002 for patients with COVID-19 at the end of the study, from 0 to 7 scores, with those scores < 3 means no risk of malnutrition and >= 3 means malnutrition.
Change from baseline Serum ferritin level at end of the trial
Change in serum ferritin at the end of the trial as ferritin is considered as a COVID-19 fatality predictor.
Change from baseline serum Interleukin-6 concentration at end of the trial
Change in IL-6 at the end of the trial as it represent the cytokine storm and it is considered as a COVID-19 fatality predictor
Change from baseline serum C-reactive protein concentration at end of the trial
Change in C-reactive protein in the serum at the end of the trial which reflect the acute phase
Change from baseline serum Tumor necrosis factor-α concentration at end of the trial
Change in the TNF a in the serum at the end of study as it represent severity of the cytokine storm
Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial
plasma MCP-1 represent severity of the cytokine storm

Secondary Outcome Measures

Change from baseline Weight at end of the trial
Body weight in Kg
Height
stature in cm
Change from baseline BMI at end of the trial
Claculation of BMI according to weight / square Height
Change from baseline mid arm circumference at end of the trial
changes of MAC in cm
Change from baseline triceps skin-fold thickness at end of the trial
changes of TSF in mm
Change from baseline MAMA at end of the trial
). The mid-arm muscle area (MAMA) will be calculated according to the following equation: {MAMA= (MAC - π x TSF)2 / 4π}.
Change from baseline percentage of peripheral O2 saturation at end of the trial
changes in the percentage of peripheral O2 saturation by an oximeter
Change from baseline degree of body temperature at end of the trial
changes in the degree of body temperature by infrared thermometer
Change from baseline count the total leukocyte at end of the trial
change in the count from complete blood counts
Change from baseline differential lymphocytic count at end of the trial
change in the count from complete blood counts
Change from baseline Neutrophil count at end of the trial
change in the count from complete blood counts
Change from baseline neutrophil to lymphocyte ratio at end of the trial
change in the rations calculated by division of the neutrophil count by the lymphocyte count

Full Information

First Posted
March 23, 2020
Last Updated
September 18, 2020
Sponsor
King Saud University
search

1. Study Identification

Unique Protocol Identification Number
NCT04323228
Brief Title
Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19
Acronym
ONSCOVID19
Official Title
Anti-inflammatory/Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19: A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Unknown status
Study Start Date
September 1, 2020 (Actual)
Primary Completion Date
December 1, 2020 (Anticipated)
Study Completion Date
December 30, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
King Saud University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
COVID-19 pandemic threatens patients, societies and healthcare systems around the world. The host immunity determines the progress of the disease and its lethality. The associated cytokine storm mainly affects the lungs; leading to acute lung injury with variable degrees. Modulation of cytokine production using Immunonutrition is a novel concept that has been applied to other diseases. Using specific nutrients such as n3- fatty acids and antioxidant vitamins in extraordinary doses modulate the host immune response and ameliorate the cytokine storm associated with viral diseases such as COVID-19. In this proposal, we will conduct a prospective double-blinded controlled trial for 14 days on 30 SARS-CoV-2 positive cases. The participant will be randomly assigned to two groups (n=20/each); intervention (IG) and placebo (PG) groups. The IG group will be provided with an anti-inflammatory and antioxidant oral supplement (OS) on a daily basis, while the PG will be given an isocaloric placebo. Basal and weekly nutritional screening, as well as recording of anthropometric, clinical and biochemical parameters, will be done. The main biochemical parameters include serum ferritin level, cytokine storm parameters (interleukin-6, Tumor necrosis factor-α, and monocyte chemoattractant protein 1), C-reactive protein, total leukocyte count, differential lymphocytic count and neutrophil to lymphocyte ratio. It is expected that the anti-inflammatory-antioxidant OS might help in the reduction of the COVID-19 severity with more preservation of the nutritional status of infected cases.
Detailed Description
Subjects: A total of 40 participants will be enrolled in this double-blinded prospective, randomized controlled trial. All participants will sign a written consent after details of the study have been fully explained to them. Later on, they will be randomly allocated into two study groups; intervention group (IG, n=20) and placebo group (PG, n=20). Computer-generated random numbers will be used to randomize the participants into one of two intervention groups. The study protocol will be approved by the IRB committee in King Khalid University Hospital, King Saud University Medical city. This clinical trial will be registered in the clinicaltrials.gov registry. Settings: All participants will be SARS-CoV-2 positive cases admitted to King Khalid University Hospital. Study protocol: All study participants will be instructed to either consume one capsule of oral supplement enriched in antioxidants vitamins or placebo. The OS will be served in opaque capsules of the same size, shape and color and should be ingested in the morning under the supervision of a nurse. The OS should not be consumed before the time of a meal. The composition of one capsule of the intervention-OS includes: enriched in vitamin A, C, E, Selenium and Zinc. The composition of one capsule of the intervention-supplement includes: 1500 mcg vitamin A (as β-carotene), 250 mg Vitamin C, 90 mg vitamin E, 15 ug Selenium, and 7.5 mg Zinc. The composition of the placebo will have the same weight of cellulose, and zero concentrations of vitamin A, C, E, Selenium and zinc. All participants will be assessed at the start and reassessed again after 1 week and after 14-days period. The assessment will include nutritional screening by Nutritional risk screening 2002 (NRS-2002), Subjective global assessment (SGA), and Global Leadership Initiative on Malnutrition (GLIM) criteria. Besides anthropometric measures, clinical Global Leadership Initiative on Malnutrition (GLIM). also, anthropometric measurements, clinical assessment, and biochemical data will be measured. Statistical analysis: The Statistical Package for the Social Sciences (SPSS) version 25 will be used for analysis. The descriptive statistics for continuous variables will be presented as mean ± standard deviation, while other categorical variables as percentages. The independent sample t-test will be used for comparison between the IG and PG groups. For repeated measures at multiple points of time will be tested by Friedman's two-way ANOVA. The Pearson correlation coefficient will be applied to correlate some relevant variables. All these tests were performed with 80% power and a 5% level of significance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19
Keywords
COVID-19, Antioxidant ONS, Cytokine storm

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Participants will be randomly allocated into two study groups; intervention group (IG, n=20) and placebo group (PG, n=20). Computer-generated random numbers will be used to randomize the participants into one of two intervention groups.
Masking
ParticipantCare Provider
Masking Description
The intervention-supplement and isocaloric-placebo will be served in the same shape, size and color. the care providers (nurses, dietitians) will not know members of each groups or the nature or composition of the ONS.
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
the intervention groups will receive daily oral antioxidant supplement enriched in vitamin A, C, E, Selenium and Zinc. The composition of one capsule of the intervention-supplement includes: 1500 mcg vitamin A (as β-carotene), 250 mg Vitamin C, 90 mg vitamin E, 15 ug Selenium, and 7.5 mg Zinc.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo group will receive daily intervention in form of cellulose-containing gelatin capsules with the same color and shape.
Intervention Type
Dietary Supplement
Intervention Name(s)
Oral supplement enriched in antioxidants
Intervention Description
the intervention group will receive a commercially available antioxidant supplement, which will be given to patients with COVID-19 in the morning after breakfast.
Intervention Type
Dietary Supplement
Intervention Name(s)
cellulose-containing placebo capsules
Intervention Description
The placebo group will receive an oral supplement at the same time in the same shape/size/color.
Primary Outcome Measure Information:
Title
Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial
Description
Changes in scores of the NRS-2002 for patients with COVID-19 at the end of the study, from 0 to 7 scores, with those scores < 3 means no risk of malnutrition and >= 3 means malnutrition.
Time Frame
up to 3 months
Title
Change from baseline Serum ferritin level at end of the trial
Description
Change in serum ferritin at the end of the trial as ferritin is considered as a COVID-19 fatality predictor.
Time Frame
up to 3 months
Title
Change from baseline serum Interleukin-6 concentration at end of the trial
Description
Change in IL-6 at the end of the trial as it represent the cytokine storm and it is considered as a COVID-19 fatality predictor
Time Frame
up to 3 months
Title
Change from baseline serum C-reactive protein concentration at end of the trial
Description
Change in C-reactive protein in the serum at the end of the trial which reflect the acute phase
Time Frame
up to 3 months
Title
Change from baseline serum Tumor necrosis factor-α concentration at end of the trial
Description
Change in the TNF a in the serum at the end of study as it represent severity of the cytokine storm
Time Frame
up to 3 months
Title
Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial
Description
plasma MCP-1 represent severity of the cytokine storm
Time Frame
up to 3 months
Secondary Outcome Measure Information:
Title
Change from baseline Weight at end of the trial
Description
Body weight in Kg
Time Frame
up to 3 months
Title
Height
Description
stature in cm
Time Frame
up to 1 month
Title
Change from baseline BMI at end of the trial
Description
Claculation of BMI according to weight / square Height
Time Frame
up to 3 months
Title
Change from baseline mid arm circumference at end of the trial
Description
changes of MAC in cm
Time Frame
up to 3 months
Title
Change from baseline triceps skin-fold thickness at end of the trial
Description
changes of TSF in mm
Time Frame
up to 3 months
Title
Change from baseline MAMA at end of the trial
Description
). The mid-arm muscle area (MAMA) will be calculated according to the following equation: {MAMA= (MAC - π x TSF)2 / 4π}.
Time Frame
Up to 3 months
Title
Change from baseline percentage of peripheral O2 saturation at end of the trial
Description
changes in the percentage of peripheral O2 saturation by an oximeter
Time Frame
up to 3 months
Title
Change from baseline degree of body temperature at end of the trial
Description
changes in the degree of body temperature by infrared thermometer
Time Frame
up to 3 months
Title
Change from baseline count the total leukocyte at end of the trial
Description
change in the count from complete blood counts
Time Frame
up to 3 months
Title
Change from baseline differential lymphocytic count at end of the trial
Description
change in the count from complete blood counts
Time Frame
up to 3 months
Title
Change from baseline Neutrophil count at end of the trial
Description
change in the count from complete blood counts
Time Frame
up to 3 months
Title
Change from baseline neutrophil to lymphocyte ratio at end of the trial
Description
change in the rations calculated by division of the neutrophil count by the lymphocyte count
Time Frame
up to 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Confirmed SARS-CoV-2 infection COVID-19 patient in stable condition (i.e., not requiring ICU admission). Exclusion Criteria: Tube feeding or parenteral nutrition. Pregnant or lactating women Admission to ICU > 24 hours participation in another study including any forms of supplementation or disease specific ONS.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mahmoud M.A. Abulmeaty, M.D., FACN
Phone
00966548155983
Email
mabulmeaty@ksu.edu.sa
Facility Information:
Facility Name
Prince Mohamed BinAbdulaziz Hospital
City
Riyadh
ZIP/Postal Code
14214
Country
Saudi Arabia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Abdulla Abdulsalam, MD
Phone
00966112616462
Email
research-dept@pmah.com

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
all IPD that underlie results in a publication will be shared
IPD Sharing Time Frame
starting 6 months after publication.
IPD Sharing Access Criteria
Access will be available for any researcher interested in this type of research on considerable consent.
Citations:
PubMed Identifier
28397943
Citation
Abulmeaty MM, Almajwal AM, Almadani NK, Aldosari MS, Alnajim AA, Ali SB, Hassan HM, Elkatawy HA. Anthropometric and central obesity indices as predictors of long-term cardiometabolic risk among Saudi young and middle-aged men and women. Saudi Med J. 2017 Apr;38(4):372-380. doi: 10.15537/smj.2017.4.18758.
Results Reference
background
PubMed Identifier
11895145
Citation
Grimm H, Calder PC. Immunonutrition. Br J Nutr. 2002 Jan;87 Suppl 1:S1. doi: 10.1079/bjn2001450. No abstract available.
Results Reference
background
PubMed Identifier
17922951
Citation
Calder PC. Immunonutrition in surgical and critically ill patients. Br J Nutr. 2007 Oct;98 Suppl 1:S133-9. doi: 10.1017/S0007114507832909.
Results Reference
background
PubMed Identifier
32150360
Citation
Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2023 Aug 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK554776/
Results Reference
background
PubMed Identifier
28877163
Citation
Das SK, Chisti MJ, Sarker MHR, Das J, Ahmed S, Shahunja KM, Nahar S, Gibbons N, Ahmed T, Faruque ASG, Rahman M, J Fuchs G 3rd, Al Mamun A, John Baker P. Long-term impact of changing childhood malnutrition on rotavirus diarrhoea: Two decades of adjusted association with climate and socio-demographic factors from urban Bangladesh. PLoS One. 2017 Sep 6;12(9):e0179418. doi: 10.1371/journal.pone.0179418. eCollection 2017.
Results Reference
background
PubMed Identifier
30655992
Citation
Harada K, Minami H, Ferdous T, Kato Y, Umeda H, Horinaga D, Uchida K, Park SC, Hanazawa H, Takahashi S, Ohota M, Matsumoto H, Maruta J, Kakutani H, Aritomi S, Shibuya K, Mishima K. The Elental(R) elemental diet for chemoradiotherapy-induced oral mucositis: A prospective study in patients with oral squamous cell carcinoma. Mol Clin Oncol. 2019 Jan;10(1):159-167. doi: 10.3892/mco.2018.1769. Epub 2018 Nov 16.
Results Reference
background
PubMed Identifier
31986264
Citation
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum In: Lancet. 2020 Jan 30;:
Results Reference
background
PubMed Identifier
22028151
Citation
Kim H. Glutamine as an immunonutrient. Yonsei Med J. 2011 Nov;52(6):892-7. doi: 10.3349/ymj.2011.52.6.892.
Results Reference
background
PubMed Identifier
12880610
Citation
Kondrup J, Allison SP, Elia M, Vellas B, Plauth M; Educational and Clinical Practice Committee, European Society of Parenteral and Enteral Nutrition (ESPEN). ESPEN guidelines for nutrition screening 2002. Clin Nutr. 2003 Aug;22(4):415-21. doi: 10.1016/s0261-5614(03)00098-0.
Results Reference
background
PubMed Identifier
12663270
Citation
McCowen KC, Bistrian BR. Immunonutrition: problematic or problem solving? Am J Clin Nutr. 2003 Apr;77(4):764-70. doi: 10.1093/ajcn/77.4.764.
Results Reference
background
PubMed Identifier
26315574
Citation
Mariette C. Immunonutrition. J Visc Surg. 2015 Aug;152 Suppl 1:S14-7. doi: 10.1016/S1878-7886(15)30005-9. Erratum In: J Visc Surg. 2016 Feb;153(1):83.
Results Reference
background
PubMed Identifier
29878555
Citation
McCarthy MS, Martindale RG. Immunonutrition in Critical Illness: What Is the Role? Nutr Clin Pract. 2018 Jun;33(3):348-358. doi: 10.1002/ncp.10102.
Results Reference
background
PubMed Identifier
32125452
Citation
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3. No abstract available. Erratum In: Intensive Care Med. 2020 Apr 6;:
Results Reference
background
PubMed Identifier
22390970
Citation
Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32. doi: 10.1128/MMBR.05015-11.
Results Reference
background
PubMed Identifier
25516320
Citation
Teo BW, Toh QC, Chan XW, Xu H, Li JL, Lee EJ. Assessment of muscle mass and its association with protein intake in a multi-ethnic Asian population: relevance in chronic kidney disease. Asia Pac J Clin Nutr. 2014;23(4):619-25. doi: 10.6133/apjcn.2014.23.4.01.
Results Reference
background
Links:
URL
https://books.google.com.sa/books?id=d2HvAgAAQBAJ&pg=PA17&lpg=PA17&dq=immunonutrition+virus&source=bl&ots=VUneSrxucb&sig=ACfU3U0bKU0mAdShOEvzIAMifj7SNE47Lw&hl=en&sa=X&redir_esc=y#v=onepage&q=immunonutrition%20virus&f=false
Description
Immunonutrition: Interactions of Diet, Genetics, and Inflammation - Google Books. In Immunonutrition: Interactions of Diet, Genetics, and Inflammation

Learn more about this trial

Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19

We'll reach out to this number within 24 hrs